for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Pharmaxis Ltd.

PXS.AX

Latest Trade

0.13AUD

Change

0.01(+6.25%)

Volume

456,633

Today's Range

0.12

 - 

0.13

52 Week Range

0.07

 - 

0.17

As of on the Australian Stock Exchange Ltd ∙ Minimum 15 minute delay

Pricing

Previous Close
0.12
Open
0.12
Volume
456,633
3M AVG Volume
30.78
Today's High
0.13
Today's Low
0.12
52 Week High
0.17
52 Week Low
0.07
Shares Out (MIL)
452.82
Market Cap (MIL)
57.94
Forward P/E
-4.90
Dividend (Yield %)
--

Next Event

Q3 2021 Pharmaxis Ltd Cashflow Reports

Latest Developments

更多

Pharmaxis Sells Australian Distribution Rights For A$2M

Pharmaxis Sells Distribution Rights For Bronchitol In Russia

Pharmaxis Announces A$4.4 Mln Placement

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Pharmaxis Ltd.

Pharmaxis Ltd is a clinical stage drug development company engaged in developing drugs for inflammatory and fibrotic diseases and focused on myelofibrosis. The Company has two approved respiratory products, Bronchitol and Aridol. The Bronchitol is used for the treatment of cystic fibrosis to help patient’s clear mucus from their lungs. Aridol is a lung function test designed to help doctors diagnose and manage asthma by detecting active airway inflammation through measuring airway hyper-responsiveness. The Company's development pipeline assets include a topical pan-Lysyl Oxidase (LOX) inhibitor in development for scar revision, keloid scarring and scarring from burn wounds; a series of Lysyl Oxidase Like 2 (LOXL2) inhibitors targeting fibrotic diseases of the kidney, lung, liver, and heart; and an anti-inflammatory dual Semicarbazide-Sensitive Amine Oxidase (SSAO)/ Monoamine oxidase B (MAOB) inhibitor targeting Duchenne Muscular Dystrophy.

Industry

Biotechnology & Drugs

Contact Info

20 Rodborough Rd

FRENCHS FOREST, NSW

2086

Australia

+61.2.94547200

http://www.pharmaxis.com.au/

Executive Leadership

Malcolm John McComas

Non-Executive Independent Chairman of the Board

Gary Jonathan Phillips

Chief Executive Officer, Managing Director, Executive Director

David Morris McGarvey

Chief Financial Officer, Company Secretary

Brett Charlton

Medical Director

Wolfgang G. Jarolimek

Head - Drug Discovery

Key Stats

2.00 mean rating - 1 analysts
Sell
Hold
Buy
Revenue (MM, AUD)

2019

0.0K

2020

0.0K

2021

0.0K

2022(E)

0.0K
EPS (AUD)

2019

-0.050

2020

-0.035

2021

-0.010

2022(E)

-0.026
Price To Earnings (TTM)
--
Price To Sales (TTM)
2.54
Price To Book (MRQ)
20.29
Price To Cash Flow (TTM)
318.33
Total Debt To Equity (MRQ)
222.21
LT Debt To Equity (MRQ)
150.79
Return on Investment (TTM)
-10.94
Return on Equity (TTM)
-8.61

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up